SCHEMBL6481541

SCHEMBL6481541

OC[C@@H](O)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNA5 P22460 7/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
SCN5A Q14524 1/20 0.46
KCND3 Q9UK17 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
KCNH2 Q12809 1/20 0.43
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 1/20 0.42
IDO1 P14902 1/20 0.41
KCNE1 P15382 2/20 0.41
MAPT P10636 1/20 0.41
CYP2D6 P10635 2/20 0.41
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL211788 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL30663811 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL1856673 0.85 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL7306898 0.85 KDM4E (0.49) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL30910020 0.84 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL31744336 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL506917 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL7268370 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL29767197 0.83 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5
SCHEMBL6575099 0.82 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3KCNA5KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347031-B1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2025-10-29 EP claimed
US-11827627-B2 N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-11-28 US claimed
WO-2005042490-A1 BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-05-12 WO claimed
WO-2005042490-A1 BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-05-12 WO disclosed
WO-2005003140-A1 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2005-01-13 WO disclosed
US-20050004161-A1 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents AGOURON PHARMACEUTICALS, INC. 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004161-A1 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents ZC3HAV1, IRF3, BRD4 SLC6A2 4391/4885SLC6A4 2941/4885SLC6A3 3516/4885
US-11827627-B2 N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN2B SLC6A2 225/4885SLC6A4 169/4885SLC6A3 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.